<DOC>
	<DOCNO>NCT01367496</DOCNO>
	<brief_summary>This open-label , Phase I study . Study treatment entail four-way crossover among three single , ascend , subcutaneous dose one intravenous dose MNTX six healthy normal male volunteer . Blood sample obtain determine plasma pharmacokinetics , dose proportionality subcutaneous dos , absolute bioavailability versus intravenous dose .</brief_summary>
	<brief_title>Pharmacokinetics Bioavailability Single Subcutaneous Doses Methylnaltrexone Versus Intravenous Dose</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Subject weight 60 80 kg 2 . Subject nonsmoker 3 . Subject good physical health , base history , physical exam , appropriate laboratory diagnostics test screen evidence clinically significant chronic medical condition . 1 . Subject know hypersensitivity methylnaltrexone , naltrexon opioids 2 . Subject consume prescription medication within past two week , overthecounter ( OTC ) product within seven day , experimental medication within 30 day prior study screen , drug halflife longer three day within 10 halflives ( &gt; 30 day ) screen 3 . Subject consume barbiturates inducer inhibitor CYP450 within 3 month screen 4 . Subject history evidence cardiovascular , gastrointestinal , hepatic , neurological , pulmonary , renal significant chronic illness .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>